Author:
Roberto Michela,Panebianco Martina,Aschelter Anna Maria,Buccilli Dorelsa,Cantisani Carmen,Caponnetto Salvatore,Cortesi Enrico,d’Amuri Sara,Fofi Claudia,Ierinò Debora,Maestrini Viviana,Marchetti Paolo,Marignani Massimo,Stigliano Antonio,Vivona Luca,Santini Daniele,Tomao Silverio
Abstract
The new landscape of treatments for metastatic clear cell renal carcinoma (mRCC) is constantly expanding, but it is associated with the emergence of novel toxicities, adding to up to those observed in the tyrosine-kinase inhibitor (TKI) era. Indeed, the introduction of immune checkpoint inhibitors (ICIs) alone or in combination has been associated with the development of immune-related adverse events (irAEs) involving multiple-organ systems which, even if rarely, had led to fatal outcomes. Moreover, due to the relatively recent addition of ICIs to the previously available treatments, the potential additive adverse effects of these combinations are still unknown. A prompt recognition and management of these toxicities currently represents a fundamental issue in oncology, since it correlates with the outcome of cancer patients. Even if clinical guidelines provide indications for the management of irAEs, no specific protocol to evaluate the individual risk of developing an adverse event during therapy is currently available. A multidisciplinary approach addressing appropriate interventions aimed at reducing the risk of any insidious, severe, and/or dose-limiting toxicity might represent the most efficacious strategy to timely prevent and manage severe irAEs, allowing indirectly to improve both patients’ cancer-specific survival and quality of life. In this review, we reported a five-case series of toxicity events that occurred at our center during treatment for mRCC followed by the remarks of physicians from different specialties, pinpointing the relevant role of an integrated and extended multidisciplinary team in a modern model of mRCC patient management.
Reference88 articles.
1. Epidemiology of renal cell carcinoma;Padala;World J Oncol,2020
2. Lyon, FranceInternational Agency for Research on CancerGlobal cancer observatory: cancer today
3. I Numeri del cancro in italia. rapporto 2021. disponibile sul sito
4. PowlesT
AlbigesL
BexA
GrünwaldV
PortaC
I Numeri del cancro in italia. rapporto 2020. disponibile sul sito
5. ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma;Powles;Ann Oncology : Off J Eur Soc Med Oncol Engl,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Multidisciplinary teams in high intensity medicine;Acute Care Medicine Surgery and Anesthesia;2023-04-06
2. Pesticides and Cancer;Environmental Oncology;2023